Article

Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries.

Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, CPO Piemonte, CeRMS, University of Turin, Turin, Italy.
International Journal of Cancer (Impact Factor: 6.2). 04/2011; 129(8):1940-52. DOI: 10.1002/ijc.26135
Source: PubMed

ABSTRACT Children diagnosed with noncentral nervous system solid cancers (NCNSSC) experience several adverse late effects, including second malignant neoplasm. The aim of our study was to assess the risk of specific second malignancies after a childhood NCNSSC. Diagnosis and follow-up data on 10,988 cases of NCNSSC in children (0-14 years) were obtained from 13 registries. Standardized incidence ratios (SIRs) with 95% confidence intervals (CI) and cumulative incidence of second malignancies were computed. We observed 175 second malignant neoplasms, yielding a SIR of 4.6, 95% CI: 3.9-5.3. When considering second cancers with at least 10 occurrences, highest relative risks were found for second malignant bone tumors (SIR = 26.4, 16.6-40.0), soft tissue sarcomas (SIR = 14.1, 6.7-25.8) and myeloid leukemia (SIR = 12.7, 6.3-22.8). Significant increased risks for all malignancies combined were observed after sympathetic nervous system tumors (SIR = 11.4, 5.2-21.6), retinoblastomas (SIR = 7.3, 5.4-9.8), renal tumors (SIR = 5.7, 3.8-8.0), malignant bone tumors (SIR = 5.6, 3.7-8.2), soft tissue sarcomas (SIR = 4.7, 3.2-6.8), germ-cell, trophoblastic and other gonadal neoplasms (SIR = 2.5, 1.1-4.9), carcinomas and other malignant epithelial neoplasms (SIR = 2.2, 1.4-3.3). The highest risk of a second malignancy of any type occurred 5 to 9 years after NCNSSC (SIR = 9.9, 6.8-13.9). The cumulative incidence of second malignancies 10 years after the first neoplasm was eight times higher among NCNSSC survivors than in the general population, with the absolute difference between observed and expected cumulative incidence still increasing after 50 years of follow-up. Children who survived a NCNSSC experience a large increased risk of developing a new malignancy, even many years after their initial diagnosis.

0 Bookmarks
 · 
131 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Registry-based cancer incidence and mortality data are widely used for etiologic research, cancer control and health care monitoring and planning. The complete coverage of all cases is the key criteria of data quality but it is difficult to assess because the alternative sources of data may be flawed. The aim of our study was to examine, at a nationwide level, the completeness of the Swedish Cancer Registry (CR) regarding persons who died of cancer, based on the Cause of Death Registry (DR), and using the Hospital Discharge Registry (HDR) as an additional source of data. Individuals who died of cancer from years 1999 through 2008 recorded in DR were linked to CR and HDR. A total of 190,692 individuals were identified from DR with cancer as the underlying cause of death; the mean identification rate of concordant cancer in CR was 79.8%, depending on tumor site and age at death. Breast, bladder and prostate cancers showed the highest rate of identification, whereas bone, liver and pancreatic cancers showed the lowest rate of identification. CR had no records on 10.6% of cancer cases recorded in DR. Similarly, the identification rate in HDR was 84.5% for concordant cancer and with 9.6% of cases missing. Neither source reported cancers for 3.4% of cancer cases recorded in DR. In conclusion, some 10% of cancer deaths had no cancer records in CR or in HDR, and 3.4% were missing in both sources. The identification rate depended on tumor site, age at death and, to some extent, death outside hospital.
    International Journal of Cancer 02/2012; 131(9):2085-93. · 6.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Improvements in survival among central nervous system (CNS) tumor patients has made the risk of developing a subsequent cancer an important survivorship issue. Such a risk is likely influenced by histological and treatment differences between CNS tumors. De-identified data for 41,159 patients with a primary CNS tumor diagnosis from 9 Surveillance, Epidemiology and End Results (SEER) registries were used to calculate potential risk for subsequent cancer development. Relative risk (RR) and 95 % confidence interval (CI) of subsequent cancer was calculated using SEER*Stat 7.0.9, comparing observed number of subsequent cancers versus expected in the general United States population. For all CNS tumors studied, there were 830 subsequent cancers with a RR of 1.26 (95 % CI, 1.18-1.35). Subsequent cancers were observed in the CNS, digestive system, bones/joints, soft tissue, thyroid and leukemia. Radiotherapy was associated with an elevated risk, particularly in patients diagnosed with a medulloblastoma/primitive neuroectodermal tumor (MPNET). MPNET patients who received radiotherapy were at a significant risk for development of cancers of the digestive system, leukemia, bone/joint and cranial nerves. Glioblastoma multiforme patients who received radiotherapy were at lower risks for female breast and prostate cancers, though at an elevated risk for cancers of the thyroid and brain. Radiotherapy is associated with subsequent cancer development, particularly for sites within the field of radiation, though host susceptibility and post-treatment status underlie this risk. Variation in subsequent cancer risk among different CNS tumor histological subtypes indicate a complex interplay between risk factors in subsequent cancer development.
    Journal of Neuro-Oncology 02/2013; · 3.12 Impact Factor

Full-text (2 Sources)

View
3 Downloads
Available from
Sep 6, 2014